Girschick H J, Hamm H, Ganser G, Huppertz H I
Children's Hospital, University of Würzburg, Germany.
Scand J Rheumatol. 1995;24(2):108-11. doi: 10.3109/03009749509099294.
Non-steroidal antiinflammatory drugs (NSAIDs) are routinely used in the therapy of chronic inflammatory joint diseases in childhood. Recently the NSAID naproxen was recognized to induce pseudoporphyria. This rare photodermatitis is characterized by skin fragility and vesiculation, resulting in shallow scarring. We report 4 children with juvenile rheumatoid arthritis who developed naproxen-induced pseudoporphyria. All children had received naproxen for more than 5 months when pseudoporphyria occurred. A disorder of porphyrin metabolism was excluded by analysis of the urine, serum and erythrocytes. Previous reports on naproxen-induced pseudoporphyria described a rapid disappearance of blisters after discontinuation of treatment. However, in our patients, new lesions appeared for up to 5 weeks after discontinuation of the therapy and skin fragility was apparent for up to 6 months after cessation of treatment. Since naproxen is a widely used drug in the treatment of children with juvenile rheumatoid arthritis parents of fair-skinned children should be alerted to the possibility of this rare adverse effect.
非甾体抗炎药（NSAIDs）常用于儿童慢性炎性关节疾病的治疗。最近，人们认识到NSAID萘普生可诱发假性卟啉症。这种罕见的光皮炎的特征是皮肤脆弱和水疱形成，导致浅表瘢痕。我们报告了4例患幼年类风湿关节炎且发生萘普生诱发假性卟啉症的儿童。假性卟啉症发生时，所有儿童服用萘普生均超过5个月。通过对尿液、血清和红细胞的分析排除了卟啉代谢紊乱。先前关于萘普生诱发假性卟啉症的报告描述了停药后水疱迅速消失。然而，在我们的患者中，停药后长达5周仍有新的皮损出现，治疗停止后皮肤脆弱持续长达6个月。由于萘普生是治疗幼年类风湿关节炎儿童的常用药物，应提醒皮肤白皙儿童的家长注意这种罕见不良反应的可能性。
